Tarceva may contain lung cancer, study suggests
Tarceva given immediately after chemotherapy may prove to be the magic wand to stem the progress of lung cancer, reveal the results of a new study named Saturn.OSI Pharmaceuticals and its partner Genentech Inc, with whom the former shares the revenue from Tarceva, were pleased with the results. Colin Goddard, OSI’s chief executive officer was glad with the news and asserted that Tarceva was the company’s core asset and major source of revenue.
This entry was posted on Sunday, November 9th, 2008 at 9:39 am and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.